Drug intelligence / Profile preview

PEPR111

Development stage: Preclinical
Lead developer: Peptris Technologies
Modality: Small Molecules

Overview

PEPR111 is a preclinical-stage novel chemical entity developed by Peptris Technologies. Discovered using the company's proprietary AI-driven drug discovery platform, PEPR111 is being developed for the treatment of unspecified rare diseases. The platform leverages unsupervised learning and generative AI to design optimized, patentable, and synthesizable molecules with superior activity and drug-like properties.

Beyond the preview

Go deeper on PEPR111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEPR111.

Explore the full profile